In November it will become clear whether the corona vaccines reserved for the European Union do what they should do: protect us against Covid-19. “It will be the litmus test for the corona vaccine”, Utrecht professor Cécile van Els, who works at RIVM, told NOS.
Five of the seven vaccines are in the third test phase. This means that tens of thousands of people will receive the vaccine (or a placebo). As early as November, the vaccines from AstraZeneca, BioNTech / Pfizer and Moderna can be used to determine the extent to which their drugs are successful.
Since the initial stages of testing have been successful, it is believed that people who received the vaccine are better protected against the virus than those who received a placebo. The question is how big the difference is. “If a spectacular effectiveness emerges, manufacturers could consider applying for registration immediately,” Van Els concludes.
But she recommends completing the entire testing process to rule out serious side effects. “The more participants you have, the more insight you have on exceptional side effects.”
In the meantime, the European Medicines Agency is already examining the data from the earlier test phases in order to be able to grant a license quickly if phase 3 is successful.
Bron (nen): WE